Opus Genetics, Inc. (IRD)
4.76
-0.11
(-2.26%)
USD |
NASDAQ |
Sep 25, 16:00
4.765
0.00 (0.00%)
Pre-Market: 19:59
Opus Genetics Enterprise Value : 340.80M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 340.80M |
| September 24, 2026 | 349.89M |
| September 23, 2026 | 346.58M |
| September 22, 2026 | 373.86M |
| September 21, 2026 | 378.81M |
| September 18, 2026 | 375.51M |
| September 17, 2026 | 383.77M |
| September 16, 2026 | 394.52M |
| September 15, 2026 | 428.40M |
| September 14, 2026 | 440.80M |
| September 11, 2026 | 446.59M |
| September 10, 2026 | 449.06M |
| September 09, 2026 | 420.96M |
| September 08, 2026 | 306.08M |
| September 04, 2026 | 333.36M |
| September 03, 2026 | 327.57M |
| September 02, 2026 | 315.18M |
| September 01, 2026 | 263.93M |
| August 31, 2026 | 246.58M |
| August 28, 2026 | 252.36M |
| August 27, 2026 | 265.59M |
| August 26, 2026 | 261.45M |
| August 25, 2026 | 287.07M |
| August 24, 2026 | 280.46M |
| August 21, 2026 | 282.12M |
| Date | Value |
|---|---|
| August 20, 2026 | 287.90M |
| August 19, 2026 | 283.77M |
| August 18, 2026 | 252.36M |
| August 17, 2026 | 249.06M |
| August 14, 2026 | 245.75M |
| August 13, 2026 | 254.84M |
| August 12, 2026 | 258.15M |
| August 11, 2026 | 268.07M |
| August 10, 2026 | 249.88M |
| August 07, 2026 | 249.88M |
| August 06, 2026 | 254.84M |
| August 05, 2026 | 259.80M |
| August 04, 2026 | 254.02M |
| August 03, 2026 | 248.23M |
| July 31, 2026 | 254.02M |
| July 30, 2026 | 264.76M |
| July 29, 2026 | 234.18M |
| July 28, 2026 | 229.22M |
| July 27, 2026 | 224.26M |
| July 24, 2026 | 201.95M |
| July 23, 2026 | 188.72M |
| July 22, 2026 | 199.47M |
| July 21, 2026 | 200.29M |
| July 20, 2026 | 199.47M |
| July 17, 2026 | 217.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Faeth Therapeutics, Inc. | 544.24M |
| Perspective Therapeutics, Inc. | 54.58M |
| Rezolute, Inc. | 269.12M |
| Praxis Precision Medicines, Inc. | 7.081B |
| Nuvectis Pharma, Inc. | 517.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.098M |
| Revenue (Quarterly) | 0.755M |
| Total Expenses (Quarterly) | 8.853M |
| EPS Diluted (Quarterly) | -0.139 |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -28.92% |
| Normalized Earnings Yield | -17.99 |